Latest From Helomics Corp.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced October-November 2014.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a monthly review of emerging In Vitro Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced October through November 2014.
Device companies raised a total of $801 million in 2012’s third quarter, an 18% drop from Q2’s $977 million. Approximately $2.6 billion was spent on device acquisitions, exactly $2 billion less than Q2’s total. Diagnostic/research company financings totaled $484 million during Q3 2012, up from last quarter’s $336 million. And while diagnostic/research M&A activity was not as prolific as last quarter, tech transfer deals are seeing a resurgence.
A roundup of recent medtech mergers & acquisitions, strategic alliances, and financings.
- Contract Research, Toxicology Testing-CRO
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- Precision Therapeutics Inc.
- North America
- Parent & Subsidiaries
- Helomics Corp.
- Senior Management
Gerald Vardzel, Pres. & CEO
Michael Young, VP, Fin.
Amelia Warner, Interim COO
- Contact Info
Phone: (412) 432-1500
91 43rd St.
Pittsburgh, PA 15201
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.